Anti-cancer efficacy and survival curves
for Starpharma's novel HER-2 Targeted DEP drug conjugate, Kadcyla and Herceptin in this human ovarian cancer model are illustrated in the graphs below.
For patients in the ETF cohort transplanted in complete remission, there was a plateau in overall survival curves
beyond 13.7 years of follow-up.
This approach was chosen because time-to-event survival curves
for time to CRPC and OS endpoints were relatively complete for both treatment groups, thus providing good estimation of the time spent in each health state with little need for extrapolation.
The difference in survival between the prescribed and nonprescribed groups was evident in survival curves
after 6-7 years of follow-up.
Differences in survival curves
were determined by conducting log rank tests with post hoc comparisons.
The interaction term comparing these survival curves
was statistically significant (P = .043).
The Kaplan-Meier method was used for the survival analysis and statistics, in which the survival rate and technical survival rate were calculated, and survival curves
were generated by the Kaplan-Meier method and compared with log-rank tests.
The survival curves
were obtained by the non-parametric Kaplan-Meier method (20).
Analysis on the Kaplan-Meier survival curves
demonstrated that within 8 years after surgery, there was no significant difference in aspects of overall survival and disease-free survival between 1-month subgroup and Group B, and between 3-month subgroup and Group B; over 8 years after surgery, the disease-free survival rates in 1-month subgroup, 3-month subgroup and Group B were 79.4%, 70.6%, and 55.3%, respectively.
Univariate survival curves
were plotted using the Kaplan-Meier method, and statistical differences were determined by using the log-rank test.